Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Hendrik Zimmet"'
Autor:
Christopher M. Reid, Jeffrey Lefkovits, Harriet Carruthers, Angela Brennan, Diem Dinh, Ingrid Hopper, James Wong, Andrea Driscoll, Hendrik Zimmet, Justin A. Mariani
Publikováno v:
Heart, Lung and Circulation. 29:1782-1789
Background Multiple co-morbidities complicate initiation of medical therapy in patients with heart failure with reduced ejection fraction (HFrEF). Adherence to guidelines based on individual patient profiles is not well described. This paper examines
Autor:
Annabel Larby, David P. Nadebaum, J. Hare, Shyam S Sankjmiron, Paul Beech, Martin H Cherk, Kenneth Yap, Hendrik Zimmet, Robert Khor, Katerina Kyprianou, Thomas W. Barber
Publikováno v:
Journal of Medical Imaging and Radiation Oncology. 65:54-59
Introduction Suppression of physiological myocardial FDG activity is vital in patients undergoing PET/CT for assessment of known or suspected cardiac sarcoidosis. This study aims to evaluate the efficacy of physiological myocardial FDG suppression fo
Autor:
Bing Hui Wang, Hendrik Zimmet, L. Huang, Rohit Samuel, Henry Krum, Darren J. Creek, Bernard L. Flynn, K. Huang
Publikováno v:
Heart, Lung and Circulation. 29:S70
Autor:
Angela Brennan, Hendrik Zimmet, G. Toogood, James Wong, Justin A. Mariani, Diem Dinh, Andrea Driscoll, Harriet Carruthers, Jeffery Lefkovits, Ingrid Hopper, C. Reid, H. Connor
Publikováno v:
Heart, Lung and Circulation. 28:S159
Autor:
John D. Horowitz, Marcus Ilton, Margaret Arstall, R. B. Minson, Pupalan Iyngkaran, N. Kangaharan, Peter Bergin, John Atherton, David L Hare, Hendrik Zimmet, Merlin C. Thomas, Peter B MacDonald
Publikováno v:
Current Cardiology Reviews
Chronic heart failure (CHF) among Aboriginal/Indigenous Australians is endemic. There are also grave concerns for outcomes once acquired. This point is compounded by a lack of prospective and objective studies to plan care. To capture the essence of
Autor:
Henry Krum, Hendrik Zimmet
Publikováno v:
Journal of Pharmacy Practice and Research. 36:229-233
Pharmacotherapy for heart failure focuses on neurohormonal blocking strategies using predominantly angiotensin converting enzyme inhibitors and beta-blockers, both conferring improved outcomes in patients with systolic chronic heart failure. Despite
Autor:
Simon D. J. Gibbs, Hendrik Zimmet, Stephen B. Ting, Caroline Wong, J. Hare, Jay Hocking, Anthony P. Schwarer
Publikováno v:
Blood. 128:3557-3557
Aim: Cardiac amyloidosis is a protein deposition disease that can be difficult to diagnose and has a poor prognosis if diagnosis or treatment are delayed. The two major subtypes are AL and transthyretin (ATTR). Both have vastly different treatments s
Autor:
Pramote Porapakkham, Yusuke Sata, Andrew Forbes, Pornwalee Porapakkham, Silviu Itescu, Hendrik Zimmet, Henry Krum, Steven Joseph Haas
Publikováno v:
European journal of heart failure. 14(1)
Aims Bone marrow stem cell (BMSC) treatment of ST-segment elevation myocardial infarction (STEMI) has been primarily via the intracoronary route or via endogenous mobilization using granulocyte colony-stimulating factor (G-CSF). Studies have provided
Autor:
Hendrik Zimmet, Henry Krum
Publikováno v:
Heart, lungcirculation. 17
Heart failure is a major health problem on a global scale. Current therapies include drug treatments, lifestyle modification, device therapy and heart transplantation. However, the “holy grail” of heart failure treatment would be to achieve wides
Autor:
Hendrik Zimmet
Publikováno v:
Heart, lungcirculation. 12
Since its introduction into the clinical environment in the early nineties, the cardiac enzyme troponin has significantly changed the way we diagnose and manage acute coronary syndromes. Troponin I is a biochemical marker of myocardial injury with a